Affiliation:
1. Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, UK
2. Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, London W12 0NN, UK
Abstract
C-Met is a receptor tyrosine kinase that is overexpressed in a range of different cancer types, and has been identified as a potential biomarker for cancer imaging and therapy. Previously, a 68Ga-labelled peptide, [68Ga]Ga-EMP-100, has shown promise for imaging c-Met in renal cell carcinoma in humans. Herein, we report the synthesis and preliminary biological evaluation of an [18F]AlF-labelled analogue, [18F]AlF-EMP-105, for c-Met imaging by positron emission tomography. EMP-105 was radiolabelled using the aluminium-[18F]fluoride method with 46 ± 2% RCY and >95% RCP in 35–40 min. In vitro evaluation showed that [18F]AlF-EMP-105 has a high specificity for c-Met-expressing cells. Radioactive metabolite analysis at 5 and 30 min post-injection revealed that [18F]AlF-EMP-105 has good blood stability, but undergoes transformation—transchelation, defluorination or demetallation—in the liver and kidneys. PET imaging in non-tumour-bearing mice showed high radioactive accumulation in the kidneys, bladder and urine, demonstrating that the tracer is cleared predominantly as [18F]fluoride by the renal system. With its high specificity for c-Met expressing cells, [18F]AlF-EMP-105 shows promise as a potential diagnostic tool for imaging cancer.
Funder
UK Medical Research Council
Imperial College National Institute for Health Research Biomedical Research Center
Cancer Research UK Accelerator
Experimental Cancer Medicine’s Center
Reference51 articles.
1. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography;Floresta;Med. Res. Rev.,2022
2. c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer;Arulappu;J. Nucl. Med.,2016
3. Li, W., Zheng, H., Xu, J., Cao, S., Xu, X., and Xiao, P. (2018). Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts. PLoS ONE, 13.
4. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis;Liang;OncoTargets Ther.,2020
5. Prognostic value of c-Met in colorectal cancer: A meta-analysis;Liu;World J. Gastroenterol.,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献